Pacira Pharmaceuticals, a pharmaceutical company developing a non-opioid postsurgical analgesic, announced terms for its IPO on Thursday. The Parsippany, NJ-based company plans to raise $64 million by offering 4.25 million shares at a price range of $14-$16. At the mid-point of the proposed range, Pacira Pharmaceuticals will command a market value of $252 million. Pacira Pharmaceuticals, which was founded in 2006 and booked $17 million in sales for the 12 months ended September 30, 2010, plans to list on the NASDAQ under the symbol PCRX. Barclays Capital and Piper Jaffray are the lead underwriters on the deal, which is expected to price during the week of January 31.
